Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Triptorelin |
Synonyms | |
Therapy Description |
Triptorelin is an analog of luteinizing-hormone-releasing hormone (LHRH), which suppresses gonadotropin secretion, leading to decreased testosterone production in males (PMID: 31500470). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Triptorelin | AY-25650|CL-118,532|Detryptoreline | Triptorelin is an analog of luteinizing-hormone-releasing hormone (LHRH), which suppresses gonadotropin secretion, leading to decreased testosterone production in males (PMID: 31500470). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06282588 | Phase II | Docetaxel Leuprolide Degarelix Goserelin Triptorelin Darolutamide | Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (THUNDER) | Recruiting | BEL | 0 |
NCT02972060 | Phase II | Triptorelin Leuprolide Degarelix Goserelin Darolutamide | ODM-201 vs Androgen Deprivation Therapy in Hormone naive Prostate Cancer | Active, not recruiting | ITA | FRA | ESP | BEL | 0 |
NCT03279250 | Phase II | Goserelin Triptorelin Abiraterone + Apalutamide + Prednisone Leuprolide Apalutamide | Effects of Apalutamide Plus LHRH Agonist or Apalutamide Plus Abiraterone Acetate Plus LHRH Agonist for Six Months for Prostate Cancer Patients at High Risk for Recurrence | Completed | USA | 0 |
NCT02346253 | Phase Ib/II | Leuprolide Triptorelin Degarelix Bicalutamide Goserelin | High-Dose Brachytherapy in Treating Patients With Prostate Cancer | Active, not recruiting | USA | 0 |
NCT03944434 | Phase II | Anastrozole + Ribociclib Letrozole + Ribociclib Leuprolide Goserelin Triptorelin | FACILE: FeAsibility of First-line riboCIclib in oLdEr Patients With Advanced Breast Cancer (FACILE) | Active, not recruiting | ITA | 0 |
NCT02278185 | Phase II | Goserelin Degarelix Histrelin acetate Triptorelin Leuprolide Enzalutamide | Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer | Active, not recruiting | USA | 0 |
NCT02685397 | Phase II | Enzalutamide Triptorelin Goserelin Leuprolide | Management of Castration-Resistant Prostate Cancer With Oligometastases | Recruiting | CAN | 0 |
NCT05050084 | Phase III | Buserelin Relugolix Degarelix Goserelin Leuprolide Histrelin acetate Triptorelin Darolutamide + Goserelin Bicalutamide Darolutamide + Degarelix Darolutamide + Leuprolide Darolutamide + Triptorelin Buserelin + Darolutamide Darolutamide + Histrelin acetate Flutamide Darolutamide + Relugolix | Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score | Recruiting | USA | CAN | 0 |
NCT03678025 | Phase III | Docetaxel Nilutamide Triptorelin Bicalutamide Leuprolide Degarelix Goserelin Flutamide Prednisone Abiraterone Histrelin acetate | Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer | Recruiting | USA | CHE | 3 |
NCT03899077 | Phase II | Triptorelin Goserelin Degarelix Leuprolide Apalutamide | Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RP (SAVE) | Recruiting | BEL | 0 |
NCT00936390 | Phase III | Flutamide Goserelin Leuprolide Triptorelin Bicalutamide | Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer | Active, not recruiting | USA | CAN | 0 |
NCT04787744 | Phase II | Goserelin Degarelix Relugolix Nilutamide Triptorelin Histrelin acetate Docetaxel + Prednisone Leuprolide Apalutamide Abiraterone + Prednisone Flutamide Abiraterone + Methylprednisolone Bicalutamide Docetaxel Enzalutamide | Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer (VA STARPORT) | Recruiting | USA | 0 |
NCT06378866 | Phase II | Degarelix Goserelin Darolutamide Relugolix Triptorelin Enzalutamide Histrelin acetate Abiraterone + Prednisone Leuprolide Apalutamide | Stereotactic Body Radiation Therapy Plus Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy for Treatment of Metastatic, Recurrent Hormone-Sensitive Prostate Cancer, DIVINE Trial (DIVINE) | Recruiting | USA | 0 |
NCT05458856 | Phase III | Triptorelin | Effects of Triptorelin When Given Every 6-months Under the Skin to Adult Males With Cancer in the Prostate | Completed | NLD | LTU | FRA | ESP | DEU | CZE | BEL | 0 |
NCT03511196 | Phase I | Abiraterone + Prednisone Leuprolide Goserelin Triptorelin | Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer | Active, not recruiting | USA | 0 |
NCT04484818 | Phase III | Goserelin Leuprolide Darolutamide + Leuprolide Darolutamide + Triptorelin Triptorelin Darolutamide + Goserelin | Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study | Active, not recruiting | USA | 0 |
NCT04557059 | Phase III | Apalutamide + Triptorelin Triptorelin Apalutamide + Goserelin Apalutamide + Leuprolide Leuprolide Goserelin | A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Prostate-Specific Membrane Antigen-Positron Emission Tomography (PSMA-PET) Positive Hormone-Sensitive Prostate Cancer Participants (PRIMORDIUM) | Active, not recruiting | USA | TUR | SWE | SVK | POL | LBN | ITA | HUN | FIN | ESP | DNK | DEU | CZE | BRA | BEL | AUT | AUS | 4 |
NCT02366494 | Phase I | Leuprolide Goserelin Triptorelin Bicalutamide Docetaxel | Micro RNAs to Predict Response to Androgen Deprivation Therapy | Active, not recruiting | USA | 0 |